Nowcasting and forecasting the 2022 U.S. mpox outbreak: Support for public health decision making and lessons learned

IF 3 3区 医学 Q2 INFECTIOUS DISEASES
Kelly Charniga , Zachary J. Madewell , Nina B. Masters , Jason Asher , Yoshinori Nakazawa , Ian H. Spicknall
{"title":"Nowcasting and forecasting the 2022 U.S. mpox outbreak: Support for public health decision making and lessons learned","authors":"Kelly Charniga ,&nbsp;Zachary J. Madewell ,&nbsp;Nina B. Masters ,&nbsp;Jason Asher ,&nbsp;Yoshinori Nakazawa ,&nbsp;Ian H. Spicknall","doi":"10.1016/j.epidem.2024.100755","DOIUrl":null,"url":null,"abstract":"<div><p>In June of 2022, the U.S. Centers for Disease Control and Prevention (CDC) Mpox Response wanted timely answers to important epidemiological questions which can now be answered more effectively through infectious disease modeling. Infectious disease models have shown to be valuable tools for decision making during outbreaks; however, model complexity often makes communicating the results and limitations of models to decision makers difficult. We performed nowcasting and forecasting for the 2022 mpox outbreak in the United States using the R package EpiNow2. We generated nowcasts/forecasts at the national level, by Census region, and for jurisdictions reporting the greatest number of mpox cases. Modeling results were shared for situational awareness within the CDC Mpox Response and publicly on the CDC website. We retrospectively evaluated forecast predictions at four key phases (early, exponential growth, peak, and decline) during the outbreak using three metrics, the weighted interval score, mean absolute error, and prediction interval coverage. We compared the performance of EpiNow2 with a naïve Bayesian generalized linear model (GLM). The EpiNow2 model had less probabilistic error than the GLM during every outbreak phase except for the early phase. We share our experiences with an existing tool for nowcasting/forecasting and highlight areas of improvement for the development of future tools. We also reflect on lessons learned regarding data quality issues and adapting modeling results for different audiences.</p></div>","PeriodicalId":49206,"journal":{"name":"Epidemics","volume":"47 ","pages":"Article 100755"},"PeriodicalIF":3.0000,"publicationDate":"2024-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1755436524000161/pdfft?md5=abd65d67dc31cd4cde493adf01b7d575&pid=1-s2.0-S1755436524000161-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1755436524000161","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

In June of 2022, the U.S. Centers for Disease Control and Prevention (CDC) Mpox Response wanted timely answers to important epidemiological questions which can now be answered more effectively through infectious disease modeling. Infectious disease models have shown to be valuable tools for decision making during outbreaks; however, model complexity often makes communicating the results and limitations of models to decision makers difficult. We performed nowcasting and forecasting for the 2022 mpox outbreak in the United States using the R package EpiNow2. We generated nowcasts/forecasts at the national level, by Census region, and for jurisdictions reporting the greatest number of mpox cases. Modeling results were shared for situational awareness within the CDC Mpox Response and publicly on the CDC website. We retrospectively evaluated forecast predictions at four key phases (early, exponential growth, peak, and decline) during the outbreak using three metrics, the weighted interval score, mean absolute error, and prediction interval coverage. We compared the performance of EpiNow2 with a naïve Bayesian generalized linear model (GLM). The EpiNow2 model had less probabilistic error than the GLM during every outbreak phase except for the early phase. We share our experiences with an existing tool for nowcasting/forecasting and highlight areas of improvement for the development of future tools. We also reflect on lessons learned regarding data quality issues and adapting modeling results for different audiences.

预测和预报 2022 年美国麻疹疫情:支持公共卫生决策和吸取经验教训
2022 年 6 月,美国疾病控制和预防中心(CDC)Mpox 响应计划希望及时回答重要的流行病学问题,而现在可以通过传染病模型更有效地回答这些问题。传染病模型已被证明是疫情爆发期间进行决策的宝贵工具;然而,模型的复杂性往往使决策者难以了解模型的结果和局限性。我们使用 R 软件包 EpiNow2 对 2022 年美国爆发的麻风腮疫情进行了现在预测和预测。我们在全国范围内、按人口普查地区以及报告麻疹病例最多的辖区生成了即时预测/预报。建模结果在疾病预防控制中心水痘应对部门内部进行了共享,以提高对态势的认识,并在疾病预防控制中心网站上进行了公开。我们使用加权区间得分、平均绝对误差和预测区间覆盖率这三个指标对疫情爆发期间四个关键阶段(早期、指数增长、高峰和衰退)的预测进行了回顾性评估。我们比较了 EpiNow2 和天真贝叶斯广义线性模型 (GLM) 的性能。除早期阶段外,EpiNow2 模型在每个疫情爆发阶段的概率误差都小于 GLM。我们分享了使用现有工具进行 Nowcasting/forecasting 的经验,并强调了未来工具开发中需要改进的地方。我们还反思了在数据质量问题和针对不同受众调整建模结果方面的经验教训。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epidemics
Epidemics INFECTIOUS DISEASES-
CiteScore
6.00
自引率
7.90%
发文量
92
审稿时长
140 days
期刊介绍: Epidemics publishes papers on infectious disease dynamics in the broadest sense. Its scope covers both within-host dynamics of infectious agents and dynamics at the population level, particularly the interaction between the two. Areas of emphasis include: spread, transmission, persistence, implications and population dynamics of infectious diseases; population and public health as well as policy aspects of control and prevention; dynamics at the individual level; interaction with the environment, ecology and evolution of infectious diseases, as well as population genetics of infectious agents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信